Stock Analysis

Micropos Medical Full Year 2023 Earnings: kr0.17 loss per share (vs kr0.15 loss in FY 2022)

NGM:MPOS
Source: Shutterstock

Micropos Medical (NGM:MPOS) Full Year 2023 Results

Key Financial Results

  • Revenue: kr1.64m (up 50% from FY 2022).
  • Net loss: kr23.5m (loss widened by 27% from FY 2022).
  • kr0.17 loss per share (further deteriorated from kr0.15 loss in FY 2022).
revenue-and-expenses-breakdown
NGM:MPOS Revenue and Expenses Breakdown February 3rd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Surgical & Medical Equipment contributing kr1.64m. The largest operating expense was General & Administrative costs, amounting to kr23.4m (93% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of kr297.0k. Explore how MPOS's revenue and expenses shape its earnings.

Micropos Medical shares are down 6.0% from a week ago.

Risk Analysis

We should say that we've discovered 5 warning signs for Micropos Medical (4 are potentially serious!) that you should be aware of before investing here.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.